Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Hypertension. 2009 Nov 2;54(6):1313–1320. doi: 10.1161/HYPERTENSIONAHA.109.140038

Figure 2.

Figure 2

A, Representative Western blot against procollagen 1 derived from cardiac fibroblasts treated with MBG (1 or 100 nM), spironolactone (100 nM), or a combination with the corresponding quantitative data shown as the mean±SEM of 6 experiments shown below. B, Representative Western blot against procollagen 1 derived from cardiac fibroblasts treated with MBG (1 or 100 nM), canrenone (100 nM), or a combination with the corresponding quantitative data shown as the mean±SEM of 6 experiments shown below. C, Representative phosphorylated ERK1/2 (P-ERK1/2) and total ERK 1/2 (Total ERK1/2) blots as well as the quantitative ratio of P-ERK1/2/Total ERK1/2 (mean±SEM; n=9 each group) in cells treated similarly to B but harvested at 2 hours. D, The effects of MBG (1 nM), canrenone (100 nM), or a combination of the 2 treatments (15 minutes exposure) on PKC-δ expression in the cytosol and nucleus. E, The effects of MBG (1 nM), spironolactone (100 nM), or a combination of the 2 treatments (15-minute exposure) on PKC-δ expression in the cytosol and nucleus. For both D and F, representative Western blots are shown in the top portion of the panel with quantitative data (mean±SEM of 5 determinations) shown below. *P<0.05 and †P<0.01 vs control; ∥P<0.05; ¶P<0.01 vs MBG.